This site uses cookies to provide services, collect traffic data, and personalize ads. You agree by using this site.
More info
en
Press releases

NEXTCLINICS continues growing, the group acquired prominent assisted reproduction clinics in Northern Italy 

17.07.2018

Bologna/Augsburg, 17 July 2018: In late June 2018, NEXTCLINICS acquired 100% of GynePro, an Italian medical Group with in-vitro fertilization (IVF) clinics located in Bologna and Verona. With a 20 year history, GynePro is a highly experienced and renowned medical group active in the area of infertility management, assisted reproductive technology (ART), and prenatal diagnosis. GynePro’s founder, Professor Dr. Marco Filicori, will remain with the clinic as its Medical Director and will become a shareholder and investor in NEXTCLINICS. This transaction strengthens NEXTCLINICS’ position as a leading pan European provider of ART clinics and laboratories. This is NEXTCLINICS’ first major transaction in 2018, and follows a number of late 2017 investments in leading fertility centers and laboratories across Europe, valued at 80 million Euro. The valuation of the GynePro transaction will not be disclosed.

“Our expansion strategy must reflect NEXTCLINICS’ promise to our clients: offer the best medical facilities, clinical experts and services. GynePro has an outstanding reputation in the Italian IVF and academic community, is a large IVF clinic in Italy and Professor Filicori is one of the most respected and experienced clinicians and reproductive medicine scientists in Europe. Recognizing that Italy is a key market for us, our first option was the GynePro Group because of their top quality and reputation. We have every intention of continuing to invest in Italy, both through organic growth and acquisitions”, explains Miroslaw Herden, CEO of NEXTCLINICS.

“The leadership at NEXTCLINICS provides improved opportunities to enhance and expand the range and quality of services offered to our patients than GynePro could as a stand-alone organization. By joining the NEXTCLINICS family, our patients can take full advantage of a wide variety of high level services, including the largest European egg and sperm donation programs, and complementary disciplines such as genetics and specialized laboratory services, most notably the ones provided by the Archimed Group,” said Professor Marco Filicori, GynePro Medical Director and Founder.

“We are delighted with our new partner, we feel they are a perfect fit for NEXTCLINICS. We believe there is great potential in the consolidation of the market of reproductive medicine clinics and related services throughout Europe by providing highly qualified specialized services, coupled with the highest possible standards,” said Michael Bretterbauer, Business Development Director for South Europe at NEXTCLINICS.

NEXTCLINICS can confirm that there will be no changes to current operations or management of GynePro.

NEXTCLINICS European Portfolio Growing

NEXTCLINICS International invested 80 million Euro in in 2017 and forecasted investments of up to 200 million Euro in 2018. GynePro joins a portfolio which includes the Archimed Group, an Italian center for specialized genetics, laboratory and diagnostic services for more than 600 healthcare facilities, the ProCrea Group in Lugano offering IVF and specialized diagnostic services as well as plastic surgery and genetics, IMER in Valencia and Denia Spain, a leader in egg and sperm donation in Europe as well as the Praxisklinik Frauenstraße Clinic in Ulm, Germany, Genetika Plzen and the GEST Centre of Reproductive Medicine & Gynecology in Prague, the Czech Republic.

NEXTCLINICS has also invested in other facilities including hospitals, medical laboratories and a network of blood sampling and tissue collection centers in the Czech Republic, Italy, Germany, Spain, and Switzerland.

About NEXTCLINICS

NEXTCLINICS operates a network of modern and highly specialized healthcare facilities and offer care primarily in allergology, clinical immunology, pneumology as well as other related fields. Entering the European market in 2015, this dynamically growing healthcare company with headquarters in Germany aims to foster innovative procedures in healthcare combining the latest diagnostic and treatment methods with a patient and client-centric approach and using high-tech communication technology. Services are available in the Czech Republic, Italy, Germany, Spain and Switzerland, while also serving other countries. More information at www.next-clinics.com.

About GynePro

In the last two decades the GynePro Medical Group has been at the forefront of the clinical management of women’s health in Italy, particularly in the area of reproductive disorders, infertility, and prenatal diagnosis. GynePro is based in Bologna and Verona, with affiliated clinics in several Italian regions. GynePro was founded and is directed by Professor Marco Filicori, a physician and scientist with international recognition and reputation. State of the art technology in the in-vitro fertilization (IVF) laboratory and highly qualified physicians and embryologists have allowed GynePro to achieve top clinical results in assisted reproduction. More information at www.gynepro.it.

Press release

 



Back to overview

Other articles

NL Holding announces it has secured Oaktree Capital Management as its partner for further expansion and the acquisition

NL Holding announces it has secured Oaktree Capital Management, a major global investment group, as its partner for further expansion and the acquisition of healthcare facilities in Spain, Italy, and Switzerland.

NEXTCLINICS adds the IVF Centers of Prof. Zech to portfolio and becomes one of the Europe’s 3 largest assisted reproductive technology providers

Bregenz/Salzburg/Augsburg, 1 August 2018: On the heels of acquiring Italy’s GynePro Medical Group in June 2018, NEXTCLINICS is proud to announce it will take control of 100% of The IVF Centers Prof. ZECH (Zech IVF), one of Europe’s largest networks of in-vitro fertilization (IVF) clinics with offices in Bregenz, Salzburg, Cologne, Vaduz, Niederuzwil, Pilsen and Merano. In less than a year, NEXTCLINICS has expanded to be among Europe’s top 3 IVF providers with 14 clinics in its portfolio across the continent. NEXTCLINICS now has the perfect platform to invest into further European and global growth. Because of the enormous overlap of philosophy and principles between the two groups, Zech IVF’s founder Professor Dr. Herbert Zech has become shareholder in NEXTCLINICS. Further, Professor Zech will join the Medical Board in a leading position and will support the further international expansion of NEXTCLINICS. The transaction is part of the NEXTCLINICS plan to invest up to EUR 200 million in 2018. The valuation of the Zech IVF transaction will not be disclosed and is subject to Austrian anti-trust regulatory approval.

Press releases overview...




NEXTCLINIC operates a network of modern and highly specialized healthcare facilities and offer care primarily in allergology, clinical immunology, pneumology, phtiseology as well as other related fields. We are a leading provider of assisted reproduction services (IVF), gynecology and obstetrics, and offer a diverse range of complimentary services. Our central fundamental guiding principle lies in a responsible and accountable approach to patients, one where information is shared, and where patients are encouraged to take an active role in their own wellbeing.

With presence on multiple European markets, NEXTCLINIC offers patients from around the world the opportunity to choose a preferred location and enjoy the benefits of unique destinations. Customers enjoy healthcare services, but also a wide range of complimentary services.

Project permeating across several disciplines, providing patients the ability to identify and integrate a whole new social group to gain many benefits. It creates opportunities for testing of your health and makes information about health and healthy lifestyle accessible.

The NEXTLIFE application change trends in patient communication with a physician. We allow quality and fast testing, where the patient can determine the time and method of examination. The NEXTLIFE magazine focuses on a healthy lifestyle.

NEXTLAB provides fast and accurate laboratory diagnostics on biological material for private GPs, outpatient specialists, hospitals, patients without a health insurance policy, and those who request laboratory services beyond standard testing.

NEXTLAB builds upon 20 years of experience with its own labs and sample collection centres, offering a wide range of lab tests based on the latest diagnostic methods, devices and technologies. Tests that are not carried out in our labs are forwarded to partner labs in compliance with a strict pre-analytical procedure.

You are leaving NEXTCLINICS website.

For more information about selected services, you will be redirected to %s.
Do you want to continue?

STAY ON THIS PAGE CONTINUE